Overview

Study of the Drug B11-FC (Botulism Treatment)

Status:
NOT_YET_RECRUITING
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
Study of the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of the drug B11-FC with a single application in adults
Phase:
PHASE1
Details
Lead Sponsor:
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Treatments:
Botulinum Toxins, Type A